Positive Clinical Results for ALN-PCS, Reported at ATVB 2012

Positive Clinical Results for ALN-PCS, Reported at ATVB 2012

Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%.



 The new data also highlight continued improved efficacy and tolerability for Alnylam’s second-generation lipid nanoparticle (LNP) delivery technology.



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.